HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effects of azithromycin in bronchiolitis obliterans syndrome after hematopoietic SCT--a randomized double-blinded placebo-controlled study.

Abstract
Bronchiolitis obliterans syndrome (BOS) is an important complication after hematopoietic SCT (HSCT). Recent observations suggested that azithromycin might improve lung function in BOS after HSCT. We conducted a randomized double-blinded placebo-controlled study on azithromycin in patients with BOS after HSCT. The treatment group (n=10) received oral azithromycin 250 mg daily while the control group (n=12) received placebo daily for 12 weeks. Respiratory symptoms were assessed by the St George Respiratory Questionnaires and spirometry at baseline (drug commencement), 1, 2, 3 (drug cessation) and 4 months (1 month after drug cessation). There was no significant difference in the baseline demographic characteristics between the treatment and the control groups in age, gender, time from HSCT to BOS, time since diagnosis of BOS, chronic GVHD, baseline respiratory symptom scores and baseline forced expiratory volume in 1 s (FEV(1)). Throughout and after 3 months of treatment, there were no significant changes in respiratory symptom scores and FEV(1) measurements between the treatment and the control groups. In conclusion, there was no significant benefit of 3 months of oral azithromycin on the respiratory symptoms and lung function in patients with relatively late BOS after HSCT in this randomized placebo-controlled study.
AuthorsD C L Lam, B Lam, M K Y Wong, C Lu, W Y Au, E W C Tse, A Y H Leung, Y L Kwong, R H S Liang, W K Lam, M S M Ip, A K W Lie
JournalBone marrow transplantation (Bone Marrow Transplant) Vol. 46 Issue 12 Pg. 1551-6 (Dec 2011) ISSN: 1476-5365 [Electronic] England
PMID21317934 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Anti-Bacterial Agents
  • Azithromycin
Topics
  • Administration, Oral
  • Adult
  • Anti-Bacterial Agents (administration & dosage)
  • Azithromycin (administration & dosage)
  • Bronchiolitis Obliterans (drug therapy, etiology)
  • Chronic Disease
  • Double-Blind Method
  • Female
  • Graft vs Host Disease (drug therapy, etiology)
  • Hematologic Neoplasms (therapy)
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Male
  • Middle Aged
  • Syndrome
  • Time Factors
  • Transplantation, Homologous

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: